BriaCell Therapeutics (BCTX) said Wednesday that a phase 2 study of its Bria-IMT regimen with check point inhibitors to treat metastatic breast cancer showed positive survival results.
The study showed a median survival of 17.3 months in certain patients, surpassing the 14.4 months seen for the antibody-drug conjugate treatment Trodelvy, the company said .
For triple-negative breast cancer, the company said Bria-IMT showed survival comparable to Trodelvy but significantly better than chemotherapy, with a 70% improvement.
The drug developer said it plans to further evaluate the results in an ongoing phase 3 trial focused on overall survival.
BriaCell shares rose 27% in recent premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。